Etocarlide

Etocarlide

SCHEMBL2157104

CCOc1ccc(NC(=S)Nc2ccc(OCC)cc2)cc1.N

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.96
GAA P10253 5/20 0.83
L3MBTL1 Q9Y468 1/20 0.73
ALDH1A1 P00352 8/20 0.68
KDM4E B2RXH2 2/20 0.68
LMNA P02545 5/20 0.67
KMT2A Q03164 5/20 0.64
MEN1 O00255 3/20 0.64
HTT P42858 3/20 0.64
POLB P06746 2/20 0.64
HPGD P15428 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
NSD2 O96028 1/20 0.64
BLM P54132 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
MPI P34949 1/20 0.62
CYP1A2 P05177 1/20 0.62
TDP1 Q9NUW8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Etocarlide SCHEMBL6761547 0.98 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL9367891 0.98 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL103618 0.98 MAPT (1.00) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL9263 0.98 MAPT (1.00) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL27935 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL20658914 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL120610 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL21694441 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL20994029 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL3459278 0.96 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118359736-A Borate water-resistant starch, preparation method and degradable agricultural film 青岛科技大学 2024-07-19 CN claimed
CN-114558609-B Alkylation catalyst, preparation method thereof, alkylation reaction method and catalyst regeneration method 中国石油化工股份有限公司 2023-11-10 CN claimed
CN-107694564-B Catalyst for decomposing formaldehyde and preparation method thereof 苏州吉派供应链管理有限公司 2023-10-03 CN claimed
CN-116786107-A Preparation method of porous SCR catalyst 溢通环保科技(莆田)有限公司 2023-09-22 CN claimed
CN-116641055-A Alkaline etching solution and preparation method thereof 惠州昊化电子材料有限公司 2023-08-25 CN claimed
CN-116106231-B Method for evaluating similarity between sample and breast milk in multiple dimensions 北京三元食品股份有限公司 2023-07-07 CN claimed
CN-116106231-A Method for evaluating similarity between sample and breast milk in multiple dimensions 北京三元食品股份有限公司 2023-05-12 CN claimed
US-11128950-B2 Speaker module GOERTEK INC. (CN) 2021-09-21 US claimed
US-10567869-B2 Sound-absorbing component and speaker module applying the sound-absorbing component GOERTEK INC. (CN) 2020-02-18 US claimed
US-20190253789-A1 SPEAKER MODULE GOERTEK INC. (CN) 2019-08-15 US claimed
US-20190208312-A1 SOUND-ABSORBING COMPONENT AND SPEAKER MODULE APPLYING THE SOUND-ABSORBING COMPONENT GOERTEK INC. (CN) 2019-07-04 US claimed
US-20250339395-A1 COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS NOVARTIS PHARMACEUTICALS CORP (US) 2025-11-06 US disclosed
WO-2025133966-A1 PRODUCTION OF GLUCOSYLCERAMIDE CARBOCODE S.A (PT) 2025-06-26 WO disclosed
CN-119930703-A Chlorine-free high-water-solubility Pt (II) complex and application thereof in preparation of Pt/C electrocatalyst 贵研化学材料(云南)有限公司 2025-05-06 CN disclosed
CN-119930703-A Chlorine-free high-water-solubility Pt (II) complex and application thereof in preparation of Pt/C electrocatalyst 贵研化学材料(云南)有限公司 2025-05-06 CN disclosed
US-6927291-B2 Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides PHARMASSET, LTD. (US) 2005-08-09 US disclosed
EP-1363927-A2 METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES Pharmasset Limited (US) 2003-11-26 EP disclosed
US-20020198224-A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides GILEAD PHARMASSET LLC 2002-12-26 US disclosed
WO-2002070533-A2 METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES PHARMASSET LTD. (BB) 2002-09-12 WO disclosed
EP-1022618-A1 Composition for image receiving layer and polymer film having the image receiving layer formed therefrom SKC Co., Ltd. (KR) 2000-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198224-A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides DUT, DUS2, DERA MAPT 4763/4885GAA 627/4885L3MBTL1 1037/4885
US-20250339395-A1 COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS MME, DNPEP, ANPEP MAPT 1785/4885GAA 586/4885L3MBTL1 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.